Jeff Kindler serves as Chief Executive Officer of Centrexion Therapeutics, a company focused on developing safe and effective, non-addictive treatments for chronic pain. He holds more than 30 years of experience in business and has held leadership positions at some of the world’s most recognized companies.

Mr. Kindler is a leading expert in pharmaceuticals and other health care sectors; corporate legal matters including regulation, litigation, compliance and crisis management; brand and franchise management; board and corporate governance; and executive leadership. He currently serves as an advisor or director at Lux Capital, a leading venture capital firm; the GLG Institute, a membership-based learning community for leading executives; and a number of health care companies. He is involved in a number of not-for-profit institutions, including Tufts University, where he is a Trustee Emeritus.

Prior to joining Centrexion, Mr. Kindler was the Chairman and CEO of Pfizer, the world’s largest research-based biopharmaceutical company. As CEO, he led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified its product portfolio, improved its research and development pipeline, and reshaped the company’s commercial, innovation and leadership models to drive growth and cultural change.

Earlier in his career, Mr. Kindler served as the Executive Vice President and General Counsel for McDonald’s Corporation and was the Vice President of Litigation and Legal Policy for the General Electric Company. Prior to GE, Mr. Kindler practiced civil and criminal litigation as a Partner of William & Connolly.

Mr. Kindler holds degrees from Tufts University and Harvard University, and served as an editor of the Harvard Law Review.